Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
847 stopped studies mapped to Malignant Bone Marrow Neoplasm and descendants · 88% state a reason
Over the 847 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT04054245 | PAT-1251 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera… | Phase 2 | withdrawn | Aug 13, 2019 | M.D. Anderson Cancer Center | "Company is in a process of being taken over by another pharma and the new one has different ideas… | Sponsor / business decision |
| NCT03547154 | Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^®… | Phase 2 / Phase 3 | terminated | Jun 6, 2018 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT02634827 | Midostaurin and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid… | Phase 2 | terminated | Dec 18, 2015 | Mayo Clinic | not stated | Not stated |
| NCT00167180 | Post Transplant Donor Lymphocyte Infusion | Phase 2 | terminated | Sep 14, 2005 | Masonic Cancer Center, University of Minnesota | Accrual Goal Met | Enrollment / accrual |
| NCT02360111 | GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal… | N/A | terminated | Feb 10, 2015 | Memorial Sloan Kettering Cancer Center | Lack of accrual | Enrollment / accrual |
| NCT02477787 | Randomized Study of Haploidentical Hct and Subsequent Donor nk Cell Infusion in High-risk…(DNKI-4) | Phase 2 | terminated | Jun 23, 2015 | Asan Medical Center | upon recommendation from the Data Monitoring Committee | Other (stated, no rule matched) |
| NCT01159067 | Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and… | Phase 2 | terminated | Jul 9, 2010 | City of Hope Medical Center | Low enrollment | Enrollment / accrual |
| NCT01853228 | A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children… | Phase 1 / Phase 2 | terminated | May 14, 2013 | Janssen Research & Development, LLC | EMA/PDCO acknowledged that available results from this study do not support further clinical… | Other (stated, no rule matched) |
| NCT03735446 | Prexasertib in Combination With MEC in Relapsed/Refractory AML and High Risk MDS - a… | Phase 1 | terminated | Nov 8, 2018 | Dana-Farber Cancer Institute | Sponsor Decision | Sponsor / business decision |
| NCT02421354 | Nivolumab in Treating Patients With Primary Myelofibrosis, Post-Essential Thrombocythemia… | Phase 2 | terminated | Apr 20, 2015 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT03752138 | TK216 and Decitabine in Treating Patients With Relapsed and Refractory Acute Myeloid… | Phase 1 | withdrawn | Nov 23, 2018 | M.D. Anderson Cancer Center | The supporting pharamceutical company elected not to pursue this study at this time. | Sponsor / business decision |
| NCT02749708 | Study of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk… | Phase 1 | terminated | Apr 25, 2016 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Study drug supply expired and could not be renewed. | Drug supply |
| NCT03291353 | Phase 0- Pilot Study of Pembrolizumab on Immune Cells in Patient With Refractory Acute… | Early Phase 1 | withdrawn | Sep 25, 2017 | Michael Boyiadzis | This study has closed due to slow accrual. | Enrollment / accrual |
| NCT02826642 | A Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia | Phase 1 | withdrawn | Jul 11, 2016 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT00808080 | A Clinical Trial of Cytotoxic T Cells Augmenting Autologous Hematopoietic Stem Cell…(AMLCTL) | Phase 1 / Phase 2 | terminated | Dec 15, 2008 | Thomas A. Lane, MD | lack of accrual | Enrollment / accrual |
| NCT02030405 | Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia | Phase 2 | terminated | Jan 8, 2014 | Steven E. Coutre | Regulatory | Other (stated, no rule matched) |
| NCT02627573 | Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT | Phase 2 | terminated | Dec 11, 2015 | St. Petersburg State Pavlov Medical University | Poor recruitment | Enrollment / accrual |
| NCT03381118 | Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML Patients | Phase 2 | terminated | Dec 21, 2017 | St. Petersburg State Pavlov Medical University | Unexpected toxicity | Safety / toxicity |
| NCT02900248 | CureOne Registry: Advanced Malignancy or Myelodysplasia, Tested by Standard Sequencing…(N1) | — | terminated | Sep 14, 2016 | CureOne | Registry was built to handle Medicare coverage decision on NGS, but CMS decided to not require data. | Other (stated, no rule matched) |
| NCT01116232 | Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease… | Phase 2 | terminated | May 4, 2010 | Barbara Ann Karmanos Cancer Institute | Lack of funding. | Funding |
| NCT02418000 | A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or… | Phase 1 / Phase 2 | terminated | Apr 16, 2015 | Spirita Oncology, LLC | Insufficient efficacy in Phase 1 dose-escalation portion of study | Efficacy / futility |
| NCT03187691 | Safety and PK of Oral Encochleated Amphotericin B (CAMB/MAT2203) for Antifungal… | Phase 2 | withdrawn | Jun 15, 2017 | Matinas BioPharma Nanotechnologies, Inc. | Protocol redundancy | Other (stated, no rule matched) |
| NCT03705858 | Actinium-225-Lintuzumab in Patients With Acute Myeloid Leukemia | Phase 1 | withdrawn | Oct 15, 2018 | Joseph Jurcic | Due to difficulty in finalizing the contract | Other (stated, no rule matched) |
| NCT01701323 | Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients… | Phase 1 | terminated | Oct 5, 2012 | Nohla Therapeutics, Inc. | not stated | Not stated |
| NCT03699384 | Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients… | Phase 1 / Phase 2 | withdrawn | Oct 9, 2018 | Memorial Sloan Kettering Cancer Center | Study sponsor discontinued support | Other (stated, no rule matched) |
| NCT01957644 | Phase I Dose Escalation Trial of Volasertib in Combination With Azacitidine in Patients… | Phase 1 | terminated | Oct 8, 2013 | Boehringer Ingelheim | not stated | Not stated |
| NCT01849276 | Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML | Phase 1 | terminated | May 8, 2013 | Northwestern University | Slow accrual | Enrollment / accrual |
| NCT00655395 | Treatment of Elderly Patients With Acute Myeloid Leukemia (AML) and High Risk… | Phase 1 / Phase 2 | terminated | Apr 9, 2008 | Viron Therapeutics Inc | not stated | Not stated |
| NCT02412475 | Epigenetic Reprogramming in Relapse AML | Phase 1 | terminated | Apr 9, 2015 | Michael Burke | We opened a competing study with the TACL consortium | Other (stated, no rule matched) |
| NCT02614560 | A Study of Vadastuximab Talirine Given Prior to or After Allogeneic Hematopoietic Stem… | Phase 1 / Phase 2 | terminated | Nov 25, 2015 | Seagen Inc. | not stated | Not stated |
| NCT02730195 | Pioglitazone and Tyrosine Kinase Inhibitor in Treating Patients With Relapsed Chronic… | Phase 2 | terminated | Apr 6, 2016 | Emory University | not stated | Not stated |
| NCT00074490 | Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and… | Phase 2 | terminated | Dec 15, 2003 | National Cancer Institute (NCI) | Premature closure due to inability to accrue to ARM IVD, cohorts 1 and 2 | Enrollment / accrual |
| NCT02683395 | A Study of PLX51107 in Advanced Malignancies | Phase 1 | terminated | Feb 17, 2016 | Plexxikon | Business Decision | Sponsor / business decision |
| NCT02785900 | Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older…(CASCADE) | Phase 3 | terminated | May 30, 2016 | Seagen Inc. | Due to safety; specifically a higher rate of deaths, including fatal infections, in the SGN33A arm… | Safety / toxicity |
| NCT03438344 | Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications… | Phase 2 | withdrawn | Feb 19, 2018 | City of Hope Medical Center | PI Withdrawal | Other (stated, no rule matched) |
| NCT02676323 | Panobinostat With Fludarabine and Cytarabine for Treatment of Children With Acute Myeloid… | Phase 1 | terminated | Feb 8, 2016 | St. Jude Children's Research Hospital | Slow accrual | Enrollment / accrual |
| NCT02587871 | Donor Cellular Therapy After Cytarabine in Treating Patients With Intermediate-Risk Acute… | Phase 2 | withdrawn | Oct 27, 2015 | University of Southern California | PI decided not to pursue study | Other (stated, no rule matched) |
| NCT03365661 | QUILT-3.034: Non-Myeloablative TCRa/b Deplete Haplo HSCT With Post ALT-803 for AML | Phase 2 | withdrawn | Dec 7, 2017 | Masonic Cancer Center, University of Minnesota | Sponsor halted study. | Other (stated, no rule matched) |
| NCT00212407 | New York Blood Center National Cord Blood Program | Early Phase 1 | terminated | Sep 21, 2005 | New York Blood Center | Study NCT01656603 supersedes this study; FDA IND 6637 | Other (stated, no rule matched) |
| NCT02709083 | Dasatinib or Nilotinib Followed by Imatinib in Patients With Newly Diagnosed, Chronic… | Phase 2 | terminated | Mar 15, 2016 | Emory University | Original principal investigator left institution | Investigator |
| NCT00043810 | Study of Gelonin Purging of Autologous Stem Cells for Transplantation | Phase 1 / Phase 2 | terminated | Aug 15, 2002 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT01904643 | Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or… | Phase 1 | terminated | Jul 22, 2013 | Stanford University | Accrual factor | Enrollment / accrual |
| NCT00038870 | Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes | N/A | withdrawn | Jun 7, 2002 | M.D. Anderson Cancer Center | Slow accrual. | Enrollment / accrual |
| NCT02992860 | Single Agent JNJ-56022473 in MDS and AML Patients FAILING HYPOMETHYLATING AGENT BASED…(SAMBA) | Phase 2 | terminated | Dec 14, 2016 | GWT-TUD GmbH | Enrollement was stopped due to a recommendation by the IDMC/FDA for a parallel clinical trial with… | Enrollment / accrual |
| NCT03207334 | iCare4: Genomic Signatures With Midostaurin in Acute Myeloid Leukemia (UF-HEM-004) | Phase 2 | withdrawn | Jul 2, 2017 | University of Florida | Insufficient funding | Funding |
| NCT02641002 | A Study of CC-90002 in Subjects With Acute Myeloid Leukemia (AML) and High-risk… | Phase 1 | terminated | Dec 29, 2015 | Celgene | Preliminary monotherapy data in relapsed/refractory AML and high-risk MDS did not offer a… | Other (stated, no rule matched) |
| NCT01866553 | Nilotinib Plus Pegylated Interferon-α2b in CML | Phase 2 | terminated | May 31, 2013 | Amsterdam UMC, location VUmc | insufficient enrollment | Enrollment / accrual |
| NCT00038649 | Therapy of Early Chronic Phase CML With Higher-Dose Gleevec, Alpha Interferon, and… | Phase 2 | terminated | Jun 4, 2002 | M.D. Anderson Cancer Center | Sponsor discontinued providing study drug. | Other (stated, no rule matched) |
| NCT01846624 | Decitabine and Midostaurin in Treating Older Patients With Newly Diagnosed Acute Myeloid… | Phase 2 | terminated | May 3, 2013 | David Iberri | Accrual factor | Enrollment / accrual |
| NCT02415608 | Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis | Phase 2 | terminated | Apr 14, 2015 | Jason Robert Gotlib | Slow accrual | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Aug 13, 2019source: clinicaltrials